Posts associated with "MEK Inhibitors"

image_print

ICARE Social Media Post February 2020

Advances in Treatment: Plexiform Neurofibromas in NF1

The FDA has granted a breakthrough therapy designation to selumetinib, a MEK inhibitor, for treatment of inoperable plexiform neurofibromas. These types of neurofibromas are almost exclusively seen in individuals with neurofibromatosis type 1 (NF1). These plexiform neurofibromas are benign tumors on the nerve sheaths and can develop anywhere in the body. These tumors typically cause …

Continue reading »

Permanent link to this article: https://inheritedcancer.net/post22820/